Lucid Capital Markets Upgrades Tvardi Therapeutics Inc (TVRD) to Buy Feb 4, 2026 06:09AM
Tvardi Therapeutics (TVRD) Misses Q3 EPS by 59c Nov 13, 2025 06:19PM
Raymond James Downgrades Tvardi Therapeutics Inc (TVRD) to Market Perform Oct 14, 2025 06:35AM
Barclays Downgrades Tvardi Therapeutics Inc (TVRD) to Equalweight Oct 13, 2025 04:07PM
Tvardi Therapeutics Inc (TVRD) PT Lowered to $15 at BTIG Oct 13, 2025 12:13PM


Oct 13, 2025 12:12PM Tvardi Therapeutics Inc (TVRD) PT Lowered to $10 at Oppenheimer
Oct 13, 2025 10:12AM Cantor Fitzgerald Downgrades Tvardi Therapeutics Inc (TVRD) to Neutral
Oct 13, 2025 09:59AM Piper Sandler Downgrades Tvardi Therapeutics Inc (TVRD) to Neutral
Oct 13, 2025 05:31AM Barclays Starts Tvardi Therapeutics Inc (TVRD) at Overweight
Jul 14, 2025 06:24AM Raymond James Starts Tvardi Therapeutics Inc (TVRD) at Outperform
Jul 11, 2025 06:46AM Cantor Fitzgerald Starts Tvardi Therapeutics Inc (TVRD) at Overweight
Jun 12, 2025 03:52AM Piper Sandler Starts Tvardi Therapeutics Inc (TVRD) at Overweight
May 30, 2025 04:07PM Tvardi Therapeutics (TVRD) Files for 2.08M Share Offering by Selling Stockholders
May 28, 2025 05:09AM BTIG Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD)
May 21, 2025 06:02AM Oppenheimer Starts Tvardi Therapeutics Inc (TVRD) at Outperform, PT $65
May 15, 2025 06:05AM BTIG Starts Tvardi Therapeutics Inc (TVRD) at Buy
Apr 30, 2025 07:11AM Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy